BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35468992)

  • 21. A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.
    Wang Y; Takeshita H; Yamamoto K; Huang Y; Wang C; Nakajima T; Nozato Y; Fujimoto T; Yokoyama S; Hongyo K; Nakagami F; Akasaka H; Takami Y; Takeya Y; Sugimoto K; Rakugi H
    FASEB J; 2021 Mar; 35(3):e21419. PubMed ID: 33566370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. d-Galactose treatment increases ACE2, TMPRSS2, and FURIN and reduces SERPINA1 mRNA expression in A549 human lung epithelial cells.
    Baristaite G; Gurwitz D
    Drug Dev Res; 2022 May; 83(3):622-627. PubMed ID: 34677831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection.
    Carlos AJ; Ha DP; Yeh DW; Van Krieken R; Tseng CC; Zhang P; Gill P; Machida K; Lee AS
    J Biol Chem; 2021; 296():100759. PubMed ID: 33965375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells.
    Zhou L; Huntington K; Zhang S; Carlsen L; So EY; Parker C; Sahin I; Safran H; Kamle S; Lee CM; Lee CG; Elias JA; Campbell KS; Naik MT; Atwood WJ; Youssef E; Pachter JA; Navaraj A; Seyhan AA; Liang O; El-Deiry WS
    bioRxiv; 2020 Sep; ():. PubMed ID: 32793908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.
    Lapaillerie D; Charlier C; Guyonnet-Dupérat V; Murigneux E; Fernandes HS; Martins FG; Magalhães RP; Vieira TF; Richetta C; Subra F; Lebourgeois S; Charpentier C; Descamps D; Visseaux B; Weigel P; Favereaux A; Beauvineau C; Buron F; Teulade-Fichou MP; Routier S; Gallois-Montbrun S; Meertens L; Delelis O; Sousa SF; Parissi V
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0008322. PubMed ID: 35861550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis.
    Xu J; Xu X; Jiang L; Dua K; Hansbro PM; Liu G
    Respir Res; 2020 Jul; 21(1):182. PubMed ID: 32664949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low dose radiation therapy attenuates ACE2 depression and inflammatory cytokines induction by COVID-19 viral spike protein in human bronchial epithelial cells.
    Wen K; Bai C; Zhao H; Zhou P; Gao S; Guan H; Song M
    Int J Radiat Biol; 2022; 98(10):1532-1541. PubMed ID: 35319335
    [No Abstract]   [Full Text] [Related]  

  • 29. Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor.
    Cheng X; Liu YQ; Wang GZ; Yang LN; Lu YZ; Li XC; Zhou B; Qu LW; Wang XL; Cheng YX; Liu J; Tao SC; Zhou GB
    Oncotarget; 2017 Jan; 8(2):2681-2693. PubMed ID: 27835873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
    Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
    J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obesogenic and Ketogenic Diets Distinctly Regulate the SARS-CoV-2 Entry Proteins ACE2 and TMPRSS2 and the Renin-Angiotensin System in Rat Lung and Heart Tissues.
    Da Eira D; Jani S; Ceddia RB
    Nutrients; 2021 Sep; 13(10):. PubMed ID: 34684358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19.
    Fu J; Zhou B; Zhang L; Balaji KS; Wei C; Liu X; Chen H; Peng J; Fu J
    Mol Biol Rep; 2020 Jun; 47(6):4383-4392. PubMed ID: 32410141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension.
    Fuchs E; Rudnik-Jansen I; Dinesen A; Selnihhin D; Mandrup OA; Thiam K; Kjems J; Pedersen FS; Howard KA
    Acta Biomater; 2022 Nov; 153():411-418. PubMed ID: 36162760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asthma Associated Cytokines Regulate the Expression of SARS-CoV-2 Receptor ACE2 in the Lung Tissue of Asthmatic Patients.
    Saheb Sharif-Askari F; Goel S; Saheb Sharif-Askari N; Hafezi S; Al Heialy S; Hachim MY; Hachim IY; Mahboub B; Salameh L; Abdelrazig M; Elzain EI; Al-Muhsen S; Al-Hajjaj MS; Ratemi E; Hamid Q; Halwani R
    Front Immunol; 2021; 12():796094. PubMed ID: 35111161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathophysiological conditions induced by SARS-CoV-2 infection reduce ACE2 expression in the lung.
    Miura Y; Ohkubo H; Nakano A; Bourke JE; Kanazawa S
    Front Immunol; 2022; 13():1028613. PubMed ID: 36405683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 spike protein enhances MAP4K3/GLK-induced ACE2 stability in COVID-19.
    Chuang HC; Hsueh CH; Hsu PM; Huang RH; Tsai CY; Chung NH; Chow YH; Tan TH
    EMBO Mol Med; 2022 Sep; 14(9):e15904. PubMed ID: 35894122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity.
    Saiz ML; DeDiego ML; López-García D; Corte-Iglesias V; Baragaño Raneros A; Astola I; Asensi V; López-Larrea C; Suarez-Alvarez B
    Clin Epigenetics; 2021 Oct; 13(1):187. PubMed ID: 34635175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective Inhibition of the Interaction between SARS-CoV-2 Spike S1 and ACE2 by SPIDAR Peptide Induces Anti-Inflammatory Therapeutic Responses.
    Paidi RK; Jana M; Mishra RK; Dutta D; Pahan K
    J Immunol; 2021 Nov; 207(10):2521-2533. PubMed ID: 34645689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating angiotensin-converting enzyme 2-mediated SARS-CoV-2 entry across species.
    Zhang HL; Li YM; Sun J; Zhang YY; Wang TY; Sun MX; Wang MH; Yang YL; Hu XL; Tang YD; Zhao J; Cai X
    J Biol Chem; 2021; 296():100435. PubMed ID: 33610551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.